Rapid Improvement of Depression of Fluoxetine Combined With ATP or Phosphocreatine
Status:
Recruiting
Trial end date:
2023-07-07
Target enrollment:
Participant gender:
Summary
The clinical study is a randomized (2:1), double-blind, placebo-controlled clinical study.
Recruit patients with moderate to severe depression. After signing the informed consent,
patients who meet the inclusion criteria will be randomly assigned to the experimental group
(fluoxetine combined with ATP or phosphocreatine) and the control group (fluoxetine combined
with 0.9% sodium chloride) to received treatment. Then accessed HAMD-24, HAMA, and PHQ-9
before treatment and at one, two, and four weeks after treatment to initially explore the
safety and efficacy of ATP and phosphocreatine combined with fluoxetine to rapidly improves
moderate to severe depression.